摘要Objective: The goal of this study was to see if travoprost and β -blockers improved MDA and SOD expression as well as neuroprotection in glaucoma mice. Methods: One hundred healthy SPF SD rats were randomly allocated into five groups: travoprost and β -blocker group, travoprost group, β -blocker group, model group and blank group, with 20 rats in each group. We created a glaucoma mouse model in which the blank group and the model group received the same volume of saline, the β -blocker group received β -blocker, the travoprost group received travoprost, and the travo Prost and β -blocker groups received travo Prost and β receptor blockers. Retinal cell apoptosis level, intraocular pressure level, MDA and SOD levels were measured after drug administration. Results: The results showed that the levels of intraocular pressure, the apoptosis rate of optic nerve, SOD and MDA of retina in travoprost and β -blocker group, travoprost group, β -blocker group and model group were greater than those in blank group(P< ; 0.05). In comparison to the model group, the intraocular pressure level, optic nerve apoptosis rate, and retinal MDA level in the travoprost and β -blocker group continued to fall, while the retinal SOD level was considerably elevated(P< ; 0.05). The continuous application of travoprost and β -blocker resulted in a constant drop in intraocular pressure, optic nerve apoptosis rate and MDA level in the retina, whereas the SOD level was dramatically elevated(P< ; 0.05). Conclusion: In glaucoma mice, travoprost in combination with a β -blocker can greatly increase MDA expression, SOD and neuroprotection.;
Abstract：Objective: The goal of this study was to see if travoprost and β -blockers improved MDA and SOD expression as well as neuroprotection in glaucoma mice. Methods: One hundred healthy SPF SD rats were randomly allocated into five groups: travoprost and β -blocker group, travoprost group, β -blocker group, model group and blank group, with 20 rats in each group. We created a glaucoma mouse model in which the blank group and the model group received the same volume of saline, the β -blocker group received β -blocker, the travoprost group received travoprost, and the travo Prost and β -blocker groups received travo Prost and β receptor blockers. Retinal cell apoptosis level, intraocular pressure level, MDA and SOD levels were measured after drug administration. Results: The results showed that the levels of intraocular pressure, the apoptosis rate of optic nerve, SOD and MDA of retina in travoprost and β -blocker group, travoprost group, β -blocker group and model group were greater than those in blank group(P< ; 0.05). In comparison to the model group, the intraocular pressure level, optic nerve apoptosis rate, and retinal MDA level in the travoprost and β -blocker group continued to fall, while the retinal SOD level was considerably elevated(P< ; 0.05). The continuous application of travoprost and β -blocker resulted in a constant drop in intraocular pressure, optic nerve apoptosis rate and MDA level in the retina, whereas the SOD level was dramatically elevated(P< ; 0.05). Conclusion: In glaucoma mice, travoprost in combination with a β -blocker can greatly increase MDA expression, SOD and neuroprotection.;
LIU Hai-hua, LIN Yi-long, ZHONG Jun-mu, LIU Jian-qiang. Improvement of MDA and SOD Expression and Optic Neuroprotection in Glaucoma Mice by Travoprost and β-Blocker[J]. 中国生物医学工程学报(英文版）, 2023, 32(2): 73-78.
LIU Hai-hua, LIN Yi-long, ZHONG Jun-mu, LIU Jian-qiang. Improvement of MDA and SOD Expression and Optic Neuroprotection in Glaucoma Mice by Travoprost and β-Blocker. Chinese Journal of Biomedical Engineering, 2023, 32(2): 73-78.
[1] Hoffmann EM, Dietlein T, Pfeiffer N.The diagnosis and treatment of glaucoma[J]. Dtsch Arztebl Int, 2020,117(13):225-234. [2] Stein JD, Khawaja AP, Weizer JS.Glaucoma in adults-screening, diagnosis, and management: A review[J]. JAMA, 2021,325(2):164-174. [3] Nazm N, Mehta R, Edward DP.Newer advances in medical management of glaucoma[J]. Indian J Ophthalmol, 2022,70(6):1920-1930. [4] El-Assal MIA, Ishak RAH, Mortada ND.Travoprost liquid nanocrystals: An innovative armamentarium for effective glaucoma therapy[J]. Pharmaceutics, 2023,15(3):954. [5] Shalash AB, Abd Elmohsen MN.Comparison between latanoprost, travoprost, and tafluprost in reducing intraocular pressure fluctuations in patients with glaucoma[J]. Eur J Ophthalmol, 2021,31(6):3018-3026. [6] Petrovski G, Heegaard S, Kolko M.Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties[J]. Acta Ophthalmol, 2022,100(7):819-827. [7] Leadbitter P, Smithers F, Tan ST.β-blocker therapy for infantile hemangioma[J]. Expert Rev Clin Pharmacol, 2020,13(8):899-915. [8] Palatnick W, Jelic T.Calcium channel blocker and beta blocker overdose, and digoxin toxicity management[J]. Emerg Med Pract, 2020,22(Suppl 9):1-42. [9] Berger D, Jakob SM, Wilkman E.Beta-blocker treatment in the critically ill: a systematic review and meta-analysis[J]. Ann Med, 2022,54(1):1994-2010. [10] Pathak A, Grassi G, Esler M.Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: Indications beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines[J]. Hypertension,2022,79(6):1153-1166.
